Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Catane

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Natural Immunity and Cell Growth Regulation|January 1, 1990
Immunologic effects of AS101 in the treatment of cancer patientsA Shani, T Tichler, R Catane, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1994
Clinical studies of liposome-encapsulated doxorubicinA Gabizon, R Isacson, E Libson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
MR-guided focused ultrasound surgery (MRgFUS) for the palliation of pain in patients with bone metastases--preliminary clinical experienceR Catane, A Beck, Y Inbar, et al.
American Journal of Human Genetics|May 1, 1997
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer familiesE Levy-Lahad, R Catane, S Eisenberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2001
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriersE Levy-Lahad, A Lahad, S Eisenberg, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1981
Follow-up neurological evaluation in patients with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapyR Catane, J G Schwade, I Yarr, et al.
American Journal of Clinical Oncology|July 28, 2001
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter studyI G Ron, N Wigler, R Borovik, et al.
International Journal of Cancer|January 3, 1996
The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal modelsB Sredni, R H Xu, M Albeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancerM E R O'Brien, N Wigler, M Inbar, et al.
Oncogene|October 6, 2009
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi originI Wolf, Y Laitman, T Rubinek, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Natural Immunity and Cell Growth Regulation|January 1, 1990
Immunologic effects of AS101 in the treatment of cancer patientsA Shani, T Tichler, R Catane, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1994
Clinical studies of liposome-encapsulated doxorubicinA Gabizon, R Isacson, E Libson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
MR-guided focused ultrasound surgery (MRgFUS) for the palliation of pain in patients with bone metastases--preliminary clinical experienceR Catane, A Beck, Y Inbar, et al.
American Journal of Human Genetics|May 1, 1997
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer familiesE Levy-Lahad, R Catane, S Eisenberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2001
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriersE Levy-Lahad, A Lahad, S Eisenberg, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1981
Follow-up neurological evaluation in patients with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapyR Catane, J G Schwade, I Yarr, et al.
American Journal of Clinical Oncology|July 28, 2001
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter studyI G Ron, N Wigler, R Borovik, et al.
International Journal of Cancer|January 3, 1996
The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal modelsB Sredni, R H Xu, M Albeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancerM E R O'Brien, N Wigler, M Inbar, et al.
Oncogene|October 6, 2009
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi originI Wolf, Y Laitman, T Rubinek, et al.
Pageof 12